Recent advances in targeted strategies for triple-negative breast cancer

S Zhu, Y Wu, B Song, M Yi, Y Yan, Q Mei… - Journal of hematology & …, 2023‏ - Springer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

PI3K inhibitors are finally coming of age

B Vanhaesebroeck, MWD Perry, JR Brown… - Nature reviews Drug …, 2021‏ - nature.com
Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

CDK4 and CDK6 kinases: From basic science to cancer therapy

A Fassl, Y Geng, P Sicinski - Science, 2022‏ - science.org
BACKGROUND Cyclins and cyclin-dependent kinases (CDKs) drive cell division. Of
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

L Galluzzi, I Vitale, S Warren… - Journal for …, 2020‏ - pmc.ncbi.nlm.nih.gov
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma

FI Montalto, F De Amicis - Cells, 2020‏ - mdpi.com
Cyclin D1, an important regulator of cell cycle, carries out a central role in the pathogenesis
of cancer determining uncontrolled cellular proliferation. In normal cells, Cyclin D1 …

A review on the role of cyclin dependent kinases in cancers

S Ghafouri-Fard, T Khoshbakht, BM Hussen… - Cancer Cell …, 2022‏ - Springer
The Cyclin-dependent kinase (CDK) class of serine/threonine kinases has crucial roles in
the regulation of cell cycle transition and is mainly involved in the pathogenesis of cancers …

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

G Petroni, A Buqué, LM Coussens… - Nature reviews Drug …, 2022‏ - nature.com
Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Mechanisms of sensitivity and resistance to CDK4/6 inhibition

M Álvarez-Fernández, M Malumbres - Cancer cell, 2020‏ - cell.com
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …

The obesity-breast cancer link: a multidisciplinary perspective

EN Devericks, MS Carson, LE McCullough… - Cancer and Metastasis …, 2022‏ - Springer
Obesity, exceptionally prevalent in the USA, promotes the incidence and progression of
numerous cancer types including breast cancer. Complex, interacting metabolic and …

Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials

B Li, J **, D Guo, Z Tao, X Hu - Cancers, 2023‏ - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICIs) are the most mature treatment of
immunotherapy and have changed the mode of cancer treatment. Recent studies showed …